SIMVASTATIN

SynDRA canonical compound SYN0003483 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	HMGCR
Mechanism of action	HMGCR inhibitor
Indication	coronary heart disease \| hypercholesterolemia \| hyperlipidemia \| myocardial infarction \| stroke
Disease area	cardiology \| endocrinology \| neurology/psychiatry

All known targets

HMGCR
BCHE
CYP2C8
CYP3A4
CYP3A5
ITGB2
NR1I3
NR4A2
ache
hmg1

Mechanisms of action (all sources)

HMGCR INHIBITOR
HMG-CoA reductase inhibitor

Drug classes

Hydroxymethylglutaryl-CoA Reductase Inhibitors
HMG-CoA Reductase Inhibitor
Anticholesteremic Agents
Antimetabolites
Enzyme Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents

ATC classes

C10A · LIPID MODIFYING AGENTS, PLAIN
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
LIPID MODIFYING AGENTS, COMBINATIONS

Cross-references

PubChem CID: 54454
ChEMBL: CHEMBL1064
DrugBank: DB00641
ChEBI: CHEBI:9150
KEGG: D00434
RxNorm: 36567
PDB: A1BYZ
Wikipedia: Simvastatin
TTD: D0H0ND
LINCS BRD: BRD-K22134346

Synonyms

Reported adverse events

Myopathy
Rhabdomyolysis
Headache
Constipation
Abdominal pain
Stevens-Johnson syndrome
Eczema
Insomnia
Gastritis
Myalgia
Sinusitis
Vertigo

Look up SIMVASTATIN in the interactive SynDRA portal →